Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

Informations projet

HEcoPerMed

N° de convention de subvention: 824997

DOI

10.3030/824997

Projet clôturé

Date de signature de la CE 7 Novembre 2018

Date de début 1 Janvier 2019

Date de fin 30 Juin 2022

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 1 998 437,50

Contribution de l’UE

€ 1 998 437,50

Coordonné par

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH
Austria

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Other (3)

Budget impact models

Budget impact models developed for the 3 case studies

Cost-effectiveness models

Costeffectiveness models developed for the 3 case studies

Recommendation on the refinement of the guidance developed in WP1

Documents, reports (11)

All models populated with input data from 3 EU Member States
Report of the Stakeholder Conference
Guidance paper on health economic modelling of per-sonalised medicine
Checklist methodological quality

Checklist to assess the methodological quality of model-based economic evaluations of personalised medicine

financing and payment models

A set of appropriate financing and payment models for personalised medicine for different types of health care systems in EU

action plan

An action plan to adopt appropriate financing and payment models for personalised medicine across EU

Synthesis Report of virtual WS1 and 2
Overview of major findings from interviews
Report of the WS2
"Report on ""The Benefits & Challenges"""

Report on The Benefits Challenges of Personalised Medicine for the European Social Models of Health Care

Workshop 1 report

Open Research Data Pilot (1)

Data Management Plan

Publications

Peer reviewed articles (3)

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Auteurs: Apostolos Tsiachristas, Grant Vallance, Rositsa Koleva-Kolarova, Harriet Taylor, Luke Solomons, Giovanni Rizzo, Catherine Chaytor, Junel Miah, Sarah Wordsworth & A. Bassim Hassan
Publié dans: BMC cancer, 2022, ISSN 1471-2407
Éditeur: BioMed Central
DOI: 10.1186/s12885-022-09576-3

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Auteurs: Rositsa Koleva-Kolarova; James Buchanan
Publié dans: Applied Health Economics and Health Policy, Numéro 5, 2022, ISSN 1179-1896
Éditeur: Springer
DOI: 10.1007/s40258-021-00714-9

The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis

Auteurs: Heleen Vellekoop, Matthijs Versteegh, Simone Huygens, Isaac Corro-Ramos, László Szilberhorn, Tamás Zelei, Balázs Nagy, Apostolos Tsiachristas, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken
Publié dans: Value in Health, 2022, ISSN 1098-3015
Éditeur: Blackwell Publishing Inc.
DOI: 10.1016/j.jval.2022.01.006